FDA approves first diagnostic tool to target triple-negative breast cancer patients

pharmafile | March 11, 2019 | News story | Sales and Marketing |  Cancer, Roche, Ventana, breast cancer, pharma 

Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer (TNBC) who are eligible for treatment with the company’s immunotherapy combo of Tecentriq (atezolizumab) plus Abraxane chemotherapy.

The technology works via the specific staining of tumour cells and immune cells to determine which patients will benefit most from Roche’s combo treatment. Triple-negative breast cancer affects around 300,000 new patients around the world each year; the disease is characterised by an absence of expression of the three most common breast cancer-associated proteins – oestrogen receptor, progesterone receptor and HER2/neu – on the tumour, while PD-L1 is primarily expressed on tumour-infiltrating immune cells, rather than on the tumour cells themselves.

“Triple-negative breast cancer is an aggressive disease that, until now, has had limited treatment options,” commented Michael Heuer, CEO of Roche Diagnostics. “This assay plays a pivotal role in helping physicians identify patients that can benefit from Tecentriq therapy, providing better patient care. At Roche, we build on our capacity to research both targeted medicines and companion diagnostics under one roof, so we can provide the right treatment to the right patient at the right time.”

Matt Fellows

Related Content

Charity commits £800,000 to AI research into late breast cancer recurrence

Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate …

Most advanced breast cancer patients treated in community settings, Phesi study finds

Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings …

Amphista doses first patient in AML trial of protein degrader

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

The Gateway to Local Adoption Series

Latest content